The pharma sector saw robust revenues across several key therapeutic areas in the second quarter of 2023, with oncology, immunology, and infectious diseases leading the pack. Merck’s blockbuster cancer drug Keytruda maintained its oncology dominance with sales topping $6 billion, while AbbVie’s Humira regained its crown as the world’s best-selling drug despite new competition. Gilead’s…
Major pharma players ST Pharm, Astellas and Celltrion unveil ambitious expansion blueprints
A handful of pharma companies, including ST Pharm, Astellas Pharma, Avalon Pharma, and Celltrion have recently announced expansion projects. Major pharma expansion efforts underway in South Korea South Korean CDMO firm ST Pharm announced a second manufacturing facility in its home country — in Ansan, Gyeonggi Province. The plant is geared toward supporting burgeoning demand…
Compass Pathways names board member at pivotal moment for psychedelic industry
Compass Pathways has named biotech exec Daphne Karydas to its board. Karydas is the president and chief financial officer of Flare Therapeutics Inc., which is developing drug discovery programs targeting transcription factors for cancer and other diseases. Signs point to a potential FDA approval of psilocybin and MDMA under strict controls in the coming years,…
Pfizer beefs up while J&J slims to focus on oncology
Both Johnson & Johnson and Pfizer are gearing up to release third-quarter results. While J&J continues to display resilience with its diverse portfolio, Pfizer continues to face challenges with waning demand for its COVID-19 therapies. To date, Pfizer’s stock is down by roughly a third so far this year, reflecting concerns over its ability to…
Novartis’s Sandoz spin-off and Sanofi’s portfolio slim-down reflect pharma push toward specialization
The pharmaceutical trend toward increasing concentration appears to be gaining momentum. On September 15, Novartis shareholders approved the company’s proposed spinoff of Sandoz, the generics and biosimilars unit. The company anticipates the deal to close in early October. Similarly, Sanofi is also taking a scalpel to its operations, offloading a selection of its central nervous…
New Bayer CEO Bill Anderson’s move to cut management mirrors his Roche playbook
Bill Anderson, who assumed leadership of Bayer in June, is eyeing cuts to the company’s mid- and upper-management. In addition to the cost-savings, Anderson expects the cuts to streamline decision-making. The moves are part of Anderson’s first step in bolder initiative to revamp Bayer’s operational dynamics in the face of investor pressures. It is relatively…
Pfizer’s revenue soared in the pandemic, but its stock valuation slipped relative to industry peers since 2000
In recent years, Pfizer has emerged as the largest Big Pharma firm. In 2022, its revenue surpassed $100 billion for the first time. But even though the pandemic has cemented the company as a leading pharmaceutical powerhouse — with a healthy M&A appetite — it does not count among the upper echelon of public companies…
PBMs increasingly under fire in drug-pricing battle
As the national debate over drug pricing ramps up, Pharmacy Benefit Managers (PBMs) find themselves squarely in the spotlight. PhRMA, which has also criticized hospitals for marking up drug prices by as much as 500%, launched a seven-figure ad campaign targeting proposals in Congress to lower drug prices. PhRMA, which counts companies such as Pfizer,…
White House targets blockbusters in Medicare’s price negotiation strategy
The Biden-Harris Administration has nominated 10 drugs for price negotiations directly with pharmaceutical giants after capping monthly insulin costs at $35. Americans have historically paid more for prescription drugs than most other major economies. In a fact sheet, the White House highlighted that seniors paid $3.4 billion in out-of-pocket costs for these drugs just last…
FTC approves Amgen-Horizon merger
The Federal Trade Commission (FTC) has signed off on Amgen’s proposed $27.8 billion purchase of Horizon Therapeutics . The acquisition, one of the largest pharma deals in recent years, is set to close in the early fourth quarter of 2022. The agreement resolves an FTC lawsuit filed in May attempting to block the deal over…